EuBiologics Co., Ltd. (KOSDAQ:206650)

Market Cap	549.01B +16.0%
Revenue (ttm)	96.04B +62.4%
Net Income	24.87B
EPS	n/a
Shares Out	36.72M
PE Ratio	22.08
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	839,859
Average Volume	977,653
Open	15,420
Previous Close	15,530
Day's Range	14,750 - 15,480
52-Week Range	10,000 - 17,700
Beta	0.41
RSI	62.81
Earnings Date	Feb 2, 2026

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206650